International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 5, Issue 1, pp: (375-382), Month: April - September 2017, Available at: www.researchpublish.com

Overview of Central Serous Chorioretinopathy, Pathogenesis and Therapeutic Approaches

[1]Najlaa Samran Almutairi, [2]Shrooq Salem Mahdi Alyami, [3]Amjad Ahmad M Zuiran

Abstract: **Main objective of this study was to overview the Central serous chorioretinopathy (CSC) from different aspects, including pathogenesis and etiology of the disease up to the latest therapeutic options available for CSC. Comprehensive search was performed through PubMed, and Embase databases, for relevant articles discussing the Central serous chorioretinopathy (CSC) published up to May, 2017. CSC is a multifactorial disease that continues to be incompletely comprehended. Current imaging advancements have actually resulted in additional understanding and much better surveillance of disease development and reaction to treatment. The finest management for patients is observation alone once it is established to be central serous chorioretinopathy. If the main serous chorioretinopathy is steroid generated, an alteration of the medication must be advised to the patient's medical professional, with the decision made by the patient and the suggesting carrier. The literary works suggests that photodynamic treatment could the treatment of selection.**

Keywords: **Central serous chorioretinopathy (CSC), retinal pigment epithelial (RPE).**

1. INTRODUCTION

Central serous chorioretinopathy (CSC) is an is a condition characterized by serous retinal detachment and/or retinal pigment epithelial (RPE) detachment, adjustments most often confined to the macula, as well as connected with leakage of liquid with the RPE into the subretinal area, that was first described by Von Graefe in 1866 as persistent central syphilitic retinitis [(1)]. Various other names used to explain this disease entity consist of capillarospastic central retinitis, central angiospastic retinopathy, central serous retinopathy, and also central serous pigment epitheliopathy [(2,3)].

The pathogenesis of CSC is still not entirely understood. It is well understood that the subneural retinal liquid stems from the choroid. Initially it was believed that fluid from the choroid recede into subretinal area via flaws in limited junctions between the RPE cells due to malfunction of the blood-retinal barrier. Nevertheless, this theory does not clarify the helpful impact of laser photocoagulation which effects in irreversible RPE barrier failure. One more theory suggested that loss of typical RPE cells polarity functions as a trigger for fluid pumping from the choroid to the retina, causing a neurosensory detachment [(4)]. This concept was failed after enhanced use indocyanine environment-friendly angiography (ICGA) which exposes multifocal areas of choroidal vascular hyperpermeability in CSC, which leads to mechanical interruption of RPE obstacle with succeeding accumulation of subretinal liquid, sustaining the theory that the underlying pathophysiology goes to the choroidal level [(5,6)]. No new vessels are typically existing in CSC, but the problem appears to impact choroidal vessels. Any kind of treatment that lowers the extra of choroidal permeability could be possibly handy in CSC cases [(7)].

The treatment of main serous chorioretinopathy has actually not been reputable. Various healing strategies have actually been attempted to manage this condition, consisting of beta-blockers, acetazolamide, vitamins and non-steroidal anti-inflammatory medications, yet none of these had specific advantages [(8)]. In previous years, argon laser photocoagulation of extrafoveal leakage points was the standard of CSC treatment [(9,10)]. It is the only treatment confirmed helpful by large professional trials. Laser therapy generates a regional inflammatory response on RPE, therefore decreasing RPE leakage while choroidal hyperpermeability stay unmodified [(11)].

An additional treatment option is photodynamic therapy (PDT). PDT initially was meant to create regression of choroidal neovascularization (CNV) second to age relevant macular deterioration and lately is made use of for neovascular age-

related macular degeneration, pathologic myopia and also eye histoplasmosis created CNV treatment. The specific device of PDT on CSC is not well-known. It has actually been recommended that PDT might induce choriocapillaris damages and vascular renovation hence lowering choroidal hyperpermeability [12,13].

Main objective of this study was to overview the Central serous chorioretinopathy (CSC) from different aspects, including pathogenesis and etiology of the disease up to the latest therapeutic options available for CSC.

2. METHODS & MATERIALS

Comprehensive search was performed through PubMed, and Embase databases, for relevant articles discussing the Central serous chorioretinopathy (CSC) published up to May, 2017. Search strategy were done using Mesh terms in PubMed such as; "Central serous chorioretinopathy", "Causes", "Etiology", "Risk factors", "Pathogenesis", "treatment", "therapy", and "Phototherapy". restriction to English language articles were applied. and furthermore, references list of selected studies was screened for more relevant articles.

3. DISCUSSION

- **Clinical signs and diagnosis of patients with CSC:**

Patients with CSC most generally suffer metamorphopsia, micropsia, obscured vision, and moderate dyschromatopsia in the impacted eye. On fundus evaluation, regular signs consist of a rounded well-demarcated detachment of the neurosensory retina at the macula. PED of variable dimension could likewise take place as well as can be several or single. The subretinal fluid (SRF) can be clear or turbid/fibrinous. The turbid liquid could also develop in the sub-retinal pigment epithelial (sub-RPE) area [14,15]. In chronic CSC or in patients with old fixed disease, RPE mottling, atrophy, and clumping may be observed [16,17]. On top of that, yellow dots that are thought to stand for phagocytosed photoreceptor external sections are regularly seen just over the internal surface area of the RPE [17]. Other atypical CSC discussions consist of bullous neurosensory retinal detachment, inferior neurosensory detachment with atrophic tracts, and multifocal CSCR [18].

Examinations for CSC consist of fluorescein angiography (FA) which might reveal 'ink blot' pattern of leak or the much less typical 'smoke pile' appearance that resembles a mushroom cloud [19]. In addition, color pooling in the sub-RPE area can be seen in cases of PED. Diffuse leakage or several leaking factors can be seen in recurring, chronic, or multifocal CSCR. Indocyanine environment-friendly (ICG) angiography may show dilated choroidal vasculature representing the site of CSCR with choroidal hyperpermeability in the late stage [20,21]. Optical Coherence Tomography (OCT) can demonstrate the neurosensory detachment as well as locations of PED (**Figure 1**). Enhanced deepness imaging (EDI) OCT could reveal the thick choroid in the areas representing the neurosensory detachment [22].



Figure 1: (left) Colour fundus photograph of acute central serous chorioretinopathy presenting as serous neurosensory retinal detachment centred on fovea. The (right) photograph shows the neurosensory detachment on time domain optical coherence tomography

- **Pathogenesis and etiology of CSC:**

Guyer et alia [23] recommended a potential model for the pathogenesis of CSC based on ICG-videoangiography (ICG-V). They noted diffuse hyperpermeability around active leakage sites seen with ICG-V but not with FA. Consequently, they ended that hyperpermeability went to the degree of the choroid instead of the RPE. They suggested that choroidal hyperpermeability causes serous detachments of the RPE, which could generate a rip or decompensation of the RPE. This ultimately creates RPE leak, that is, diffusion of water, electrolytes, as well as proteins that brings about a neurosensory retinal detachment. Alterations in choroidal blood circulation could also cause choroidal ischaemia. This was first noted by Hayashi et al61 that utilized similar diagnostic devices and located locations of choroidal ischaemia along with leak of ICG color from the choriocapillaris. Fluorescein angiography (FA) and indocyanine green angiography (ICG-A) with a scanning laser ophthalmoscope and an electronic imaging system were performed to review choroidal flow adjustments in CSC by Prunte et alia 42 In their study, dilated blood vessels and also dilated draining venules in one or more choroidal lobules, complying with a localised delay in arterial dental filling, may explain choroidal hyperpermeability in the location of the damaged RPE. These monitorings are suggestive of a localised lobular inflammatory or ischaemic choroiditis. The reason of the choroidal irregularity is still unknown. The solution could hinge on changes of the autoregulation in the choroidal blood circulation [25].

RPE disorder concept, recommends that CSC arises from dysfunction of the RPE (**Figures 2a and b**) [24]. This occurs following an undefined disrespect. It causes either a few impaired RPE cells and even a single RPE cell, which causes an opposite in liquid motion in a chorioretinal direction. This, in turn, brings about leak of liquid in the subretinal area and lastly to the development of a neurosensory retinal detachment [25]. One research [26] suggested that focal damage to the RPE could reverse the direction of ion secretion as well as hence lead to better fluid motion to the retina than to the choroid. A constraint of lots of concepts of the aetiology of CSC is the lack of an ideal animal version to examine hypotheses. In an uncommon instance of the development of an animal version of CSC, nonetheless other research study [27] made small nonrhegmatogenous retinal detachments (blebs) in bunnies over regions of RPE. The RPE was harmed mechanically or by laser photocoagulation. Focal RPE damage showed up to facilitate water movement from, instead of right into, the subretinal area. Marmor66 also postulated that there is an extra scattered RPE metabolic disorder and that a focal RPE 'leakage' can overload the system so that the serous liquid gathers and persists [27].



Figure 2: (a) Fundus and red-free photo of the left eye of a patient with recurrent idiopathic CSC associated with depigmentation of the RPE. (b) FFA showing window defect and a focal RPE leak inferiorly to it.

- **Therapeutic options:**

Pharmacological treatment suggestions:

Making use of adrenergic antagonists was just one of the first attempts to treat CSCR. Adrenergic antagonists lower the impact of vasoconstriction by blocking adrenergic receptor activation generated by glucorticoids [28]. In order to reduce the adrenergic tone, thought to lag the vasospastic condition, also ablation of the stellate ganglion was utilized [29].

Later on treatment with α-adrenergic antagonists was attempted, then deserted as a result of systemic adverse effects, and currently β-adrenergic antagonists are made use of due to the fact that they have fewer negative effects [30,31].

An additional attempt was made with the carbonic anhydrase preventions that act on RPE, adding in part to the traction of the subretinal fluid [32]. Recent research studies show that both systemic acetazolamide as well as dorzolamide for topical use can enhance choroidal blood circulation [33,34,35]. In the particular situation of CSCR, in which a deficiency of choroidal blood circulation has been described, carbonic anhydrase inhibitors could be effective.

The difficulty in forecasting which patients will certainly encounter a relapsing and also chronic disease, resulting in impaired visual feature, has actually brought about a search for drugs that can be efficient in the treatment of CSCR by minimizing the serum or the task degree of endogenous glucocorticoids. Because it is guided versus one of the better well-known factors in the genesis of the CSCR, this pharmacological approach is intriguing.

Mifepristone is an antagonist of glucocorticoids and progesterone receptors with a weak antiandrogen activity and also has a good security as well as tolerability account. Furthermore, mifepristone inhibits cortisol-induced outer vasoconstriction. Ketoconazole exerts its effects by hindering some action in the steroid synthesis resulting in lowered levels of androgen, aldosterone, and also cortisol as well as in raised progesterone. These results appear to be existing at the minimum dosage of 400 mg/day. An extra action of ketoconazole is the straight antiglucocorticoid result as an antagonist at the receptor degree. Existing researches on these 2 drugs are, however, restricted by the brief follow-up and also the number of patients hired [36,37,38].

Laser photocoagulation for treatment of CSC:

Using laser photocoagulation to the leaking RPE assisted by FA has been revealed to accelerate resolution of the neurosensory detachment in CSC. Xenon laser was used at first adhered to by krypton laser; presently argon laser is a lot more commonly made use of [39,40]. Lots of level one proof studies have shown faster resolution of SRF in patients who underwent laser photocoagulation compared to control eyes [10,40,41]. This approach of treatment uses subthreshold diode laser energy in order to decrease retinal damages. It is in a similar way efficient in CSC with factor source leak yet not in eyes with diffuse leakage, and leaves no clinically obvious laser-induced damages [42,43]. Considering that there is no visible endpoint to diode micropulse laser (DMPL) application, ICG improved DMPL can be made use of to identify cured locations with post-treatment ICG angiography [42,44].

One randomized clinical test (RCT) analyzed DMPL versus argon laser photocoagulation in acute CSC [44]. Patients in both groups had full resolution of SRF at 12 weeks of follow-up. All patients had no scotomas in the DMPL group compared with 3 out of 15 patients in the argon laser group who had persistent scotomas. Comparison sensitivity was likewise substantially better in the DMPL team [44].

Photodynamic therapy:

Photodynamic therapy (PDT) with verteporfin has been used to treat both acute and chronic CSCR, as well as, to minimize reoccurrences. It is thought that PDT operates in CSCR by causing choroidal hypoperfusion, and vascular narrowing and renovating to negate choroidal hyperpermeability which is regularly located in CSCR cases [45,46].

Chan et al. reported the first case series of complete dosage, full fluence PDT in 6 patients with chronic or relentless CSCR with subfoveal leakage [47]. Many RCTs demonstrated the effectiveness of PDT. Inoue et al. reported that PDT is not effective or recurrence rate is thought to be high in eyes without any extreme hyperfluorescence on ICG [48]. Moon et al. ended that aesthetic recovery may be limited in CSCR patients with lengthy symptom period, post-PDT RPE atrophy progression, and in patients with feasible foveal injury from PDT [49]. Tsakonas et al. [50] demonstrated the effectiveness and also safety of FA-guided complete fluence PDT utilizing multiple PDT areas at the very same session for chronic CSCR. Thus also FA-guided PDT can be an efficient alternative in cases where ICG is not readily available [50].

Ruiz-Moreno et al [51] treated 82 eyes with basic PDT for chronic CSCR as well as showed that it could enhance visual acuity and also reduce main macular density (CMT). SRF has actually disappeared in all instances. In his large case collection, no patient established serious aesthetic loss or difficulties derived from PDT with an average follow-up of 12 months. 9 cases established reactive RPE hypertrophy after PDT [51]. Furthermore, neuroretinal thinning after common PDT has been explained, but is not associated with visual acuity decrease [52,53]. Morphological and also useful chorioretinal adjustments such as RPE degeneration, outside restricting membrane as well as inner segment/outer section joint line suspension have been observed after typical PDT treatment for CSCR, however were not correlated with the area of PDT treatment neither with the adjustment in visual acuity [53]. These post-PDT modifications possibly stand for sped up course of the disease, which if delegated its all-natural chronic program might create much more damage.

As a result of possible treatment-related threats such as choroidal ischemia, RPE degeneration, RPE hole, and second choroidal neovascular membrane (CNVM), some safety measures were adopted in order to lessen these risks [47,54,55]. These safety-enhanced measures consist of minimizing the dose or power (fluence) of PDT (**Figure 3**).



Figure 3: chronic CSCR showing turbid subretinal fluid (top right). Fluorescein angiography shows pin-point leakage between the optic nerve and fovea (top left). Six months after focal laser photocoagulation to the leakage site shows resolution of the subretinal fluid with enlargement of the laser scar and some atrophic RPE changes (bottom right)

4. CONCLUSION

CSC is a multifactorial disease that continues to be incompletely comprehended. Current imaging advancements have actually resulted in additional understanding and much better surveillance of disease development and reaction to treatment. The finest management for patients is observation alone once it is established to be central serous chorioretinopathy. If the main serous chorioretinopathy is steroid generated, an alteration of the medication must be advised to the patient's medical professional, with the decision made by the patient and the suggesting carrier. The literary works suggests that photodynamic treatment could the treatment of selection.

REFERENCES

[1] Von Graefe A. Ueber central recidivierende retinitis. Graefe's Arch Clin Exp Ophthalmol. 1866;12:211–215.

[2] Yannuzzi L.A., Shakin J.L., Fisher Y.L., Altomonte M.A. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology. 1984;91(12):1554–1572.

[3] Maumenee A.E. Macular diseases: clinical manifestations. Trans Am Acad Ophthalmol Otolaryngol. 1965;69:605–613.

[4] Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina. 1999;19(6):508–12. PMID: 10606450.

[5] Klais CM, Ober MD, Ciardella AP, Yanuzzi LA. Central serous chorioretinopathy. In: Ryan SJ, Hinton DR, Schachat AP, Wilkinson P, editors. Retina. USA: Mosby; 2006. pp. 1135–6.

[6] Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010 Mar;149(3):361–363. PMID: 20172062.

[7] Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, Arias L, Gómez-Ulla F. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol. 2010 May;88(3):371–6. PMID: 19958296.

[8] Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002 Sep;109(9):1723–5. PMID: 12208723.

[9] Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1979 Oct;63(10):674–7. PMID: 574397.

[10] Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983 Apr;95(4):457–66. PMID: 6682293.

[11] Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010 Sep;117(9):1792–9. PMID: 20472289.

[12] Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002 Sep;240(9):748–57. PMID: 12271373.

[13] Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002 Mar;43(3):830–41. PMID: 11867605.

[14] Spaide R.F., Campeas L., Haas A. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996; 103(12):2070–2079. discussion 2079–80.

[15] Agarwal A. 5th ed. Elsevier; 2011. Gass' atlas of macular diseases.

[16] Desai U.R., Alhalel A.A., Campen T.J., Schiffman R.M., Edwards P.A., Jacobsen G.R. Central serous chorioretinopathy in African Americans. J Natl Med Assoc. 2003;95(7):553–559.

[17] Maruko I., Iida T., Ojima A., Sekiryu T. Subretinal dot-like precipitates and yellow material in central serous chorioretinopathy. Retina. 2011;31(4):759–765.

[18] O'Connor P.R. Multifocal serous choroidopathy. Ann Ophthalmol. 1975;7(2):237–245.

[19] Bujarborua D., Nagpal P.N., Deka M. Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(3):339–351.

[20] Spaide R.F., Hall L., Haas A. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203–213.

[21] Iida T., Kishi S., Hagimura N., Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina. 1999;19(6):508–512.

[22] Imamura Y., Fujiwara T., Margolis R., Spaide R.F. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29(10):1469–1473.

[23] Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Allen H, Orlock D. Digital indocyanine-green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994; 112: 1057–1062.

[24] Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 11: 26–34.

[25] Ryan SJ. Central serous chorioretinopathy. Retina 3rd edn. 2001; 2: 1153–1181.

[26] Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefe's Arch Clin Exp Ophthalmol 1986; 224: 321–324.

[27] Negi A, Marmor MF. Experimental serous retinal detachment and focal pigment epithelial damage. Arch Ophthalmol 1984; 102: 445–449.

[28] Haigh RM, Jones CT. Effect of glucocorticoids on alpha 1-adrenergic receptor receptor binding in rat vascular smooth muscle. J Mol Endocrinol. 1990;5:42–48.

[29] Matsuura M, Ando F, Matsuura M. Stellate ganglion block therapy in central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi. 1981;85:1485–1491.

[30] Heinrich MR. Central serous retinopathy and alpha-blockaders. Bull Soc Ophtalmol Fr. 1994;74:681–683.

[31] Fabianová J, Porubská M, Cepilová Z. Central serous chorioretinopathy–treatment with beta blockers. Cesk Slov Oftalmol. 1998;54:401–404.

[32] Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002; 109:1723–1725.

[33] Dallinger S, Bobr B, Findl O, Eichler HG, Schmetterer L. Effects of acetazolamide on choroidal blood flow. Stroke. 1998;29:997–1001.

[34] Kiss B, Dallinger S, Findl O, Rainer G, Eichler HG, Schmetterer L. Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide. Am J Physiol. 1999;276:R1661–R1667.

[35] Fuchsjäger-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005;89:1293–1297.

[36] Nielsen JS, Weinreg RN, Yannuzzi L, Jampol LM. Mifepristone treatment of chronic central serous chorioretinopathy. Retina. 2007; 27:119–122.

[37] Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina. 2007;27:943–946.

[38] Golshahi A, Klingmüller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol. 2010;88:576–581.

[39] Fok A.C.T., Chan P.P.M., Lam D.S.C., Lai T.Y.Y. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 2011;46(3):160–163.

[40] Chen S.-N., Hwang J.-F., Tseng L.-F., Lin C.-J. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115(12):2229–2234.

[41] Lanzetta P., Furlan F., Morgante L., Veritti D., Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18(6):934–940.

[42] Gupta B., Elagouz M., McHugh D., Chong V., Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin Experiment Ophthalmol. 2009;37(8):801–805.

[43] Ricci F., Missiroli F., Regine F., Grossi M., Dorin G. Indocyanine green enhanced subthreshold diode-laser micropulse photocoagulation treatment of chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2009; 247(5):597–607.

[44] Verma L., Sinha R., Venkatesh P., Tewari H.K. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484] BMC Ophthalmol. 2004; 4:15.

[45] Chan W.-M., Lai T.Y.Y., Lai R.Y.K., Liu D.T.L., Lam D.S.C. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008; 115(10):1756–1765.

[46] Schmidt-Erfurth U., Laqua H., Schlötzer-Schrehard U., Viestenz A., Naumann G.O.H. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120(6):835–844.

[47] Chan W.-M., Lam D.S.C., Lai T.Y.Y., Tam B., Liu D.T.L., Chan C.K.M. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87:1453–1459.

[48] Inoue R., Sawa M., Tsujikawa M., Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol. 2010;149(3):441-6.e1-2.

[49] Moon J.W., Yu H.G., Kim T.W., Kim H.C., Chung H. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):1315–1323.

[50] Tsakonas G.D., Kotsolis A.I., Koutsandrea C., Georgalas I., Papaconstantinou D., Ladas I.D. Multiple spots of photodynamic therapy for the treatment of severe chronic central serous chorioretinopathy. Clin Ophthalmol. 2012;6:1639–1644.

[51] Ruiz-Moreno J.M., Lugo F.L., Armadá F. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol. 2010;88(3):371–376.

[52] Copete S., Ruiz-Moreno J.M., Cava C., Montero J.A. Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2012;250(6):803–808.

[53] Vasconcelos H., Marques I., Santos A.R. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1697–1705.

[54] Lee P.Y., Kim K.S., Lee W.K. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2009;53(1):52–56.

[55] Reibaldi M., Cardascia N., Longo A. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010;149(2):307-315.e2.